Clinical Trial: A Study to Investigate the Safety and Tolerability of Granulocyte-colony Stimulating Factor (G-CSF) Dosage Reduction in Mavorixafor-treated Participants With Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders

U.S., Oct. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07902830) titled 'A Study to Investigate the Safety and Tolerability of Granulocyte-colony Stimulating Factor (G-CSF) Dosage Reduction in Mavorixafor-treated Participants With Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders' on Oct. 20.

Brief Summary: The purpose of this study is to evaluate the safety and tolerability of G-CSF dosage reduction with mavorixafor in participants with autoimmune neutropenia (AIN) and chronic idiopathic neutropenia (CIN) disorders as assessed by the ability to safely reduce G-CSF dosage with mavorixafor treatment while maintaining clinically acceptable absolute neutrophil count (ANC) levels.

Stu...